Ultra-fast patient enrollment. It's about time.

News 2009

News 2010 ->
News Archive 2008 ->
News Archive 2007 ->
News Archive 2006 ->

December 2009

Week 52

Week 51

  • PSI initiated enrollment in a phase III study of a novel biological agent in patients with advanced NSCLC.
  • PSI completed a phase II study of a novel immunomodulator in patients with allergic rhinitis.
  • PSI completed the active treatment period in a phase III study of a novel cancer vaccine in patients with renal cell carcinoma.

Week 50

  • PSI completed recruitment in a phase II dose-finding study of a novel prostaglandin modulator in patients with mild to moderate persistent asthma.
  • PSI reached an interim enrollment target of 50 randomized patients in a phase II study of a novel biological agent in metastatic colorectal cancer.
  • PSI reached an interim enrollment milestone of 100 randomized patients in a phase III study of a novel antiviral in chronic hepatitis B.

Week 49

  • PSI reached an interim enrollment target of 150 randomized patients in a phase III study of a novel hormonal agent in hormone-sensitive prostate cancer.
  • PSI initiated enrollment in a phase III study of a novel dialysis product in patients with chronic kidney disease.
  • PSI completed the active treatment period in a phase III study of a novel bisphosphonate in patients with osteoporosis.

November 2009

Week 48

  • PSI reached an interim enrollment milestone of 500 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI completed a proof-of-principle study of a novel disease-modifying agent in patients with rheumatoid arthritis.
  • PSI completed a phase II dose-ranging study of a novel anticancer agent in patients with metastatic NSCLC.

Week 47

  • PSI reached an interim enrollment target of 450 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI completed the active treatment period in a phase II study of a novel immunomodulator in patients with allergic rhinitis.
  • PSI launched a phase III study of a novel biological agent in patients with gastrointestinal stromal tumors.
  • PSI completed enrollment in a phase II study of a novel antiaggregant in patients with intermittent claudication.

Week 46

  • PSI reached an interim enrollment target of 400 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI launched a phase II rollover study of a novel biological agent in patients with metastatic renal cancer.
  • PSI reached an interim enrollment objective of 100 randomized patients in a phase III study of a novel hormonal agent in hormone-sensitive prostate cancer.

Week 45

Week 44

  • PSI reached an interim enrollment target of 350 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI initiated enrollment in a phase II study of a novel biological agent in patients with metastatic colorectal cancer.
  • PSI completed enrollment in a phase II study of a novel immunomodulator in patients with allergic rhinitis.

October 2009

Week 43

  • PSI reached an interim enrollment target of 300 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI initiated enrollment in a phase III study of a novel anticancer agent in patients with metastatic pancreatic cancer.
  • PSI achieved an interim enrollment milestone of 50 randomized patients in a phase III study of a novel antiviral in chronic hepatitis B.
  • PSI reached an interim enrollment objective of 200 randomized patients in a phase III study of a novel anticancer agent in metastatic ovarian cancer.

Week 42

  • PSI completed enrollment in a phase III study of a novel anticancer agent in patients with advanced NSCLC.
  • PSI completed enrollment in a phase III study of a novel antiviral in adolescent population with chronic hepatitis B.
  • PSI initiated enrollment in a phase II study of a novel hematopoietic agent in patients with chemotherapy-induced anemia.
  • PSI completed a phase II study of a novel antiemetic in pediatric patients with post-operative nausea and vomiting.

Week 41

  • PSI reached an interim enrollment target of 250 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI reached an interim milestone of 50 randomized patients in a phase III study of a novel hormonal agent in hormone-sensitive prostate cancer.
  • PSI initiated patient enrollment in a phase II study of a novel immunomodulator in patients with allergic rhinitis.

September 2009

Week 40

  • PSI launched a proof-of-concept study of a novel immunomodulator in patients with allergic rhinitis.
  • PSI reached an interim enrollment target of 250 randomized patients in a phase II study of a novel antiaggregant in intermittent claudication.
  • PSI launched a phase III study of a novel biological agent in patients with gout.

Week 39

  • PSI launched a phase III study of a novel biological agent in patients with severe hemophilia B.
  • PSI launched a phase III study of a novel biological agent in patients with renal cell carcinoma.
  • PSI completed enrollment in a phase III study of a novel anticancer agent in patients with advanced breast cancer.

Week 38

Week 37

  • PSI completed enrollment in a phase III study of a novel bisphosphonate in patients with osteoporosis.
  • PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with metastatic colorectal cancer.
  • PSI reached an interim enrollment target of 200 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.

Week 36

August 2009

Week 35

Week 34

  • PSI launched a phase III study of a novel biological agent in patients with metastatic breast cancer.
  • PSI completed a phase II study of a novel analgesic in patients with post-surgical pain.
  • PSI completed enrollment in a proof-of-concept study of a novel anticancer agent in patients with solid tumors.
  • PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with multiple myeloma.

Week 33

  • PSI launched a phase III study of a novel biological agent in patients with advanced NSCLC.
  • PSI reached an interim enrollment target of 150 randomized patients in a phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI completed a phase II study of a novel biological agent in patients with rheumatoid arthritis.
  • PSI completed a phase II study of a novel anticancer agent with patients with advanced bladder cancer.

Week 32

  • PSI reached an interim enrollment milestone of 100 randomized patients in a phase III study of a novel anticancer agent in advanced breast cancer.
  • PSI completed the active treatment period in a phase II study of a novel antiaggregant in patients with acute myocardial infarction.
  • PSI completed a phase III study of a novel combination product in patients with COPD.
  • PSI completed a phase II study of a novel immunosuppressant in patients undergoing organ transplantation.

July 2009

Week 31

  • PSI reached an interim enrollment objective of 100 randomized patients in phase II dose-finding study of a novel prostaglandin modulator in mild to moderate persistent asthma.
  • PSI launched a phase II study of a novel antipsychotic in patients with schizophrenia.
  • PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with hormone-refractory prostate cancer.

Week 30

  • PSI launched a phase III study of a novel dialysis product in patients with chronic kidney disease.
  • PSI launched a phase III study of a novel antiviral drug in patients with chronic hepatitis C.
  • PSI initiated enrollment in a phase II study of a novel biological agent in patients with secondary acute myeloid leukemia.

Week 29

  • PSI launched a phase II study of a novel prostaglandin blocker in patients with persistent asthma.
  • PSI reached an interim enrollment milestone of 150 randomized patients in a phase II study of a novel antiaggregant in intermittent claudication.
  • PSI completed the active treatment period in a phase III study of a novel anticancer agent in patients with metastatic colorectal cancer.

Week 28

June 2009

Week 27

  • PSI reached an interim enrollment objective of 150 randomized patients in a phase III study of a novel chemotherapeutic agent in metastatic ovarian cancer.
  • PSI completed the active treatment period in a phase II study of a novel prostaglandin modulator in patients with persistent asthma.
  • PSI completed the active treatment period in a phase II study of a novel biological agent in cancer patients at risk of febrile neutropenia.
  • PSI completed the active treatment period in a phase II study of a novel biological agent in patients with ulcerative colitis.

Week 26

  • PSI initiated enrollment in a phase III study of a novel antiviral in patients with chronic hepatitis B.
  • PSI reached an interim milestone of 700 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI initiated enrollment in a phase II study of a novel biological agent in patients with inhibitor-complicated hemophilia.

Week 25

Week 24

Week 23

  • PSI launched a phase II study of a novel immunomodulator in patients with seasonal allergic rhinitis.
  • PSI reached an interim enrollment milestone of 100 randomized patients in a phase II study of a novel antiaggregant in intermittent claudication.
  • PSI reached an interim enrollment target of 650 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI completed the clinical phase of a phase III study of a novel cancer vaccine in patients with advanced renal cell carcinoma.

May 2009

Week 22

  • PSI reached an interim enrollment objective of 50 randomized patients in a phase III study of a novel antiviral in an adolescent population with chronic hepatitis B.
  • PSI reached an interim enrollment target of 350 randomized patients in a phase III study of a novel insulin formulation in type I diabetes.
  • PSI launched a phase III study of a novel antiviral in patients with chronic hepatitis C.
  • PSI completed the active treatment period in a phase II study of a novel disease-modifying agent in patients with rheumatoid arthritis.

Week 21

  • PSI launched a phase III study of a novel anticancer agent in patients with metastatic renal cancer.
  • PSI launched a dose-escalation study of a novel biological agent in patients with inhibitor-complicated hemophilia.
  • PSI initiated enrollment in a phase II dose-finding study of a novel prostaglandin modulator in patients with mild to moderate persistent asthma.
  • PSI completed the active treatment period in a phase II study of a novel biological agent in patients with rheumatoid arthritis.

Week 20

  • PSI reached an interim enrollment milestone of 50 randomized patients in a phase II study of a novel antiaggregant in intermittent claudication.
  • PSI achieved an interim enrollment target of 50 randomized patients in a phase III study of a novel anticancer agent in metastatic breast cancer.
  • PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with hormone-refractory prostate cancer.
  • PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with metastatic NSCLC.

Week 19

  • PSI completed the active treatment period in a phase II study of a novel biological agent in patients with chronic lymphocytic leukemia.
  • PSI reached an interim enrollment objective of 600 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with metastatic breast cancer.
  • PSI completed the active treatment period in a phase III study of a novel anticancer agent in patients with non-Hodgkin’s lymphoma.

April 2009

Week 18

Week 17

  • PSI completed a phase II study of a novel antiemetic in patients with chemotherapy-induced nausea and vomiting.
  • PSI complete the active treatment period in a phase III study of a novel biological agent in patients with metastatic NSCLC.
  • PSI reached an interim enrollment milestone of 550 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI reached an interim enrollment target of 500 randomized patients in a phase II/III study of a novel biological agent in metastatic renal cancer.

Week 16

  • PSI completed a phase III study of a novel antipsychotic in patients with schizophrenia.
  • PSI reached an interim enrollment objective of 100 randomized patients in a phase II study of a novel biological agent in receptor-positive advanced breast cancer.
  • PSI initiated enrollment in a phase III study of a novel biological agent in patients with inhibitor-complicated hemophilia.
  • PSI completed a phase II study of a novel opioid antagonist in patients with alcohol dependence.

Week 15

  • PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with metastatic NSCLC.
  • PSI initiated enrollment in a phase III trial of a novel bisphosphonate in patients with osteoporosis.
  • PSI completed the active treatment period in a phase II study of a novel antihyperglycemic in patients with type II diabetes.
  • PSI completed a proof-of-principle study of a novel biological agent in patients with rheumatoid arthritis.

Week 14

  • PSI reached an interim enrollment target of 100 randomized patients in a phase III study of a novel anticancer agent in metastatic ovarian cancer.
  • PSI completed enrollment in a phase III study of a novel anticancer agent in patients with small-cell lung cancer.
  • PSI met an interim enrollment objective of 50 randomized patients in a phase III study of a novel biological agent in patients with relapsing-remitting multiple sclerosis.
  • PSI completed the active treatment period in a phase II study of a novel disease-modifying agent in patients with rheumatoid arthritis.
  • PSI completed the active treatment period in a proof-of-concept study of a novel biological agent in patients with allergic rhinitis.

March 2009

Week 13

  • PSI launched a proof-of-concept study of a novel anticancer agent in patients with advanced breast cancer.
  • PSI launched a phase III study of a novel antiviral agent in patients with chronic hepatitis B.
  • PSI launched a phase II study of a novel biological agent in patients with chemotherapy-induced anemia.
  • PSI completed enrollment in a phase II study of a novel biological agent in patients with rheumatoid arthritis.
  • PSI reached an interim enrollment milestone of 500 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.

Week 12

  • PSI completed enrollment in a phase II study of a novel biological agent in cancer patients at risk of febrile neutropenia.
  • PSI completed a phase III study of a novel combination product in patients with chronic obstructive pulmonary disease.
  • PSI completed a phase III study of a novel antihyperglycemic in patients with type 2 diabetes mellitus.
  • PSI completed enrollment in a phase III study of a novel biological agent in patients with relapsing-remitting multiple sclerosis.

Week 11

  • PSI completed enrollment in a phase II study of a novel biological agent in patients with multiple myeloma.
  • PSI initiated enrollment in a phase II study of a novel antiaggregant in patients with intermittent claudication.
  • PSI completed enrollment in a phase II study of a novel anticancer agent in patients with hormone-refractory prostate cancer.
  • PSI initiated enrollment in a phase III study of a novel anticancer agent in patients with metastatic breast cancer.
  • PSI reached an interim enrollment objective of 250 randomized patients in a phase III study of a novel anticancer agent in small cell lung cancer.

Week 10

  • PSI launched a phase III study of a novel anticancer agent in patients with advanced pancreatic cancer.
  • PSI initiated enrollment in a dose-ranging study of a novel anticancer agent in patients with solid tumors.
  • PSI reached an interim enrollment objective of 450 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI launched an exploratory study of a novel biological agent in patients with severe hemophilia A.

February 2009

Week 9

  • PSI launched a phase III study of a novel anticancer agent in patients with hormone-sensitive prostate cancer.
  • PSI completed enrollment in a proof-of-principal study of a novel biological agent in patients with allergic rhinitis.
  • PSI completed enrollment in a phase II study of a novel biological agent in patients with acute myeloid leukemia.
  • PSI reached an interim enrollment target of 300 randomized patients in a phase II study of a novel biological agent for the prevention of febrile neutropenia.

Week 8

  • PSI reached an interim enrollment objective of 400 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI met an interim enrollment milestone of 100 randomized patients in a phase II study of an novel antiplatelet agent in acute coronary syndrome.
  • PSI met an interim enrollment target of 450 randomized patients in a phase II/III study of a novel biological agent in metastatic renal cancer.
  • PSI reached an interim enrollment milestone of 50 randomized patients in a phase II study of a novel biological agent in receptor-positive advanced breast cancer.
  • PSI reached an interim enrollment target of 100 randomized patients in a phase II study of a novel anticancer agent in hormone-refractory prostate cancer.

Week 7

  • PSI initiated enrollment in a proof-of-concept study of a novel biological agent in patients with allergic rhinitis.
  • PSI completed enrollment in a phase II study of a novel prostaglandin modulator in patients with persistent asthma.
  • PSI reached an interim enrollment target of 200 randomized patients in a phase II study of a novel biological agent in acute myeloid leukemia.
  • PSI completed a phase II study of a novel anticancer agent in patients with small cell lung cancer.
  • PSI reached an interim enrollment milestone of 250 randomized patients in a phase II study of a novel biological agent for the prevention of febrile neutropenia.

Week 6

  • PSI completed a phase II study of a novel antihyperglycemic in patients with type 2 diabetes.
  • PSI completed a phase II study of a novel antiaggregant agent in patients with acute myocardial infarction.
  • PSI reached an interim enrollment target of 300 randomized patients in a phase III study of a novel insulin formulation in type 1 diabetes.
  • PSI completed enrollment in a phase II study of a novel hematopoietic factor for the treatment of anemia due to chronic kidney disease.

January 2009

Week 5

  • PSI reached an interim enrollment objective of 50 randomized patients in a phase II study of a novel antiplatelet agent in acute coronary syndrome.
  • PSI reached an interim recruitment milestone of 350 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI reached an interim enrollment target of 350 randomized patients in a phase II study of a novel prostaglandin modulator in persistent asthma.
  • PSI reached an interim enrollment milestone of 200 randomized patients in a phase II study of a novel biological agent for the prevention of febrile neutropenia.

Week 4

  • PSI reached an interim enrollment objective of 150 randomized patients in a phase II study of a novel biological agent for the prevention of febrile neutropenia.
  • PSI completed enrollment in an proof-of-concept study of a novel anticancer agent in patients with solid tumors.
  • PSI completed an exploratory study of a novel biological agent in patients with allergic rhinitis.

Week 3

  • PSI initiated enrollment in a proof-of-principle study of a novel biological agent in patients with rheumatoid arthritis.
  • PSI reached an interim enrollment objective of 300 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
  • PSI completed enrollment in a phase II study of a novel antihyperglycemic in patients with type II diabetes.
  • PSI completed the active treatment period of a phase II study of a novel antiemetic for the prevention of post-operative nausea and vomiting.

Week 2

  • PSI reached an interim enrollment milestone of 100 randomized patients in a phase II study of a novel biological agent for the prevention of febrile neutropenia.
  • PSI launched a phase III study of a novel bisphosphonate in patients with osteoporosis.
  • PSI completed the active treatment part of a phase II study of a novel antibiotic in patients with hospital-acquired pneumonia.

Week 1

  • PSI reached an interim enrollment target of 200 randomized patients in a phase III study of a novel anticancer agent in small cell lung cancer.
  • PSI completed a phase II study of a novel anti-inflammatory agent in patients with osteoarthritis.
  • PSI completed the active treatment part of a phase III study of a novel antibiotic in patients with community-acquired pneumonia.

 




For more information, please contact us:

For North America Clients:

Ginny Payeur
Tel: +1 650 592 91 01
Fax: +1 650 592 91 09
E-mail: Ginny.Payeur@psi-cro.com		 For European, Japanese and ROW Clients:

Olga Alfonsova
Tel: +7 812 320 38 20
Fax: +7 812 320 38 50
E-mail: Olga.Alfonsova@psi-cro.com